{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:40Z","timestamp":1793346460736,"version":"4.5.0"},"reference-count":218,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","award":["202004047"],"award-info":[{"award-number":["202004047"]}],"id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","award":["LHGJ20220439"],"award-info":[{"award-number":["LHGJ20220439"]}],"id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.heliyon.2023.e19371","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:43:02Z","timestamp":1693312982000},"page":"e19371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9"],"prefix":"10.1016","volume":"9","author":[{"given":"Fengyuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-8619","authenticated-orcid":false,"given":"Xiaoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e19371_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2023.e19371_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2005.04.006","article-title":"Dual regulation of the LDL receptor--some clarity and new questions","volume":"1","author":"Attie","year":"2005","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib4","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib5","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1172\/JCI61919","article-title":"Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice","volume":"122","author":"Ai","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2023.e19371_bib6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"issue":"Suppl","key":"10.1016\/j.heliyon.2023.e19371_bib7","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.603910","article-title":"New insights into the regulation of lipoprotein metabolism by PCSK9: lessons from stable isotope tracer studies in human subjects","volume":"12","author":"Ying","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5551\/jat.56390","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) is independently associated with insulin resistance, triglycerides, lipoprotein(a) levels but not low-density lipoprotein cholesterol levels in a general population","volume":"28","author":"Hamamura","year":"2021","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.heliyon.2023.e19371_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk","volume":"12","author":"Arsenault","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.heliyon.2023.e19371_bib12","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2018.03.013","article-title":"Beyond LDL: what role for PCSK9 in triglyceride-rich lipoprotein metabolism?","volume":"29","author":"Dijk","year":"2018","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.113.006720","article-title":"Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms","volume":"130","author":"Rashid","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2023.e19371_bib15","first-page":"30","article-title":"A study of correlation between apolipoprotein B and dyslipidemia in type 2 diabetes patients and its relation with proteinuria- A tertiary care hospital based study","volume":"67","author":"Kumar","year":"2019","journal-title":"J. Assoc. Phys. India"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e19371_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/dom.13636","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin 9 inhibitors in people with diabetes and dyslipidaemia","volume":"21","author":"Dijk","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib17","first-page":"1","article-title":"Association of baseline low-density lipoprotein cholesterol and percentage low-density lipoprotein cholesterol reduction with statins, ezetimibe, and PCSK9 inhibition","volume":"6","author":"Marcusa","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.heliyon.2023.e19371_bib18","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jacc.2019.11.030","article-title":"Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES","volume":"75","author":"Goodman","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib20","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2023.e19371_bib21","first-page":"1141","article-title":"[The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels]","volume":"40","author":"Peng","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.heliyon.2023.e19371_bib22","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1007\/s00125-015-3762-x","article-title":"Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study","volume":"58","author":"Andersson","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.heliyon.2023.e19371_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3310","article-title":"Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients \u226565 years","volume":"36","author":"Tangelloju","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.heliyon.2023.e19371_bib24","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/ATVBAHA.121.316159","article-title":"Statins are associated with increased insulin resistance and secretion","volume":"41","author":"Abbasi","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020309","article-title":"Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study","volume":"8","author":"Karlsson","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2023.e19371_bib27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2337\/dc11-0209","article-title":"Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register","volume":"34","author":"Eliasson","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2337\/dc11-2281","article-title":"Predictors of mortality over 8 years in type 2 diabetic patients: translating research into action for diabetes (TRIAD)","volume":"35","author":"McEwen","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/2047487313494292","article-title":"LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes","volume":"21","author":"Eliasson","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.heliyon.2023.e19371_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/1753-0407.12931","article-title":"Diabetic outcomes: cardiovascular outcomes with lipid modification H2D","volume":"11","author":"Lepor","year":"2019","journal-title":"J. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/joim.12614","article-title":"Can LDL cholesterol be too low? Possible risks of extremely low levels","volume":"281","author":"Olsson","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e19371_bib33","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/db14-1710","article-title":"Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes","volume":"64","author":"Fall","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib34","article-title":"Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis","volume":"9","author":"Cai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e19371_bib35","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2023.e19371_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jdiacomp.2015.08.003","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 is associated with Lp(a) in type 2 diabetic patients","volume":"29","author":"Nekaies","year":"2015","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.heliyon.2023.e19371_bib37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40618-016-0433-9","article-title":"Analysis of the association between plasma PCSK9 and lp(a) in han Chinese","volume":"39","author":"Yang","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.heliyon.2023.e19371_bib38","first-page":"71","article-title":"Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders","volume":"28","author":"Ibarretxe","year":"2016","journal-title":"Cl\u00edn. Invest. Arterioscler."},{"key":"10.1016\/j.heliyon.2023.e19371_bib39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/pedi.12490","article-title":"Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women","volume":"18","author":"Levenson","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7956161","article-title":"Serum PCSK9 correlates with PTX3 and apolipoproteins B, A1, and C3 concentrations in patients with type 2 diabetes","volume":"2021","author":"Walu\u015b-Miarka","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.heliyon.2023.e19371_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.atherosclerosis.2011.03.023","volume":"217","author":"Brouwers","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2023.e19371_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/dmrr.2712","article-title":"Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes","volume":"32","author":"Yang","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.heliyon.2023.e19371_bib43","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrm2327","article-title":"Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes","volume":"9","author":"Muoio","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib46","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1210\/en.2002-220273","article-title":"Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification","volume":"143","author":"Cnop","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.heliyon.2023.e19371_bib47","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbadis.2019.04.012","article-title":"Cholesterol metabolism, pancreatic \u03b2-cell function and diabetes","volume":"1865","author":"Perego","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.heliyon.2023.e19371_bib48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12192-011-0265-7","article-title":"Cholesterol induces pancreatic \u03b2 cell apoptosis through oxidative stress pathway","volume":"16","author":"Lu","year":"2011","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.heliyon.2023.e19371_bib49","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/en.2009-0252","article-title":"Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells","volume":"150","author":"R\u00fctti","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.heliyon.2023.e19371_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.heliyon.2023.e19371_bib51","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1073\/pnas.0602956103","article-title":"Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice","volume":"103","author":"Le May","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2023.e19371_bib52","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1074\/jbc.M117.805069","article-title":"Estrogen receptor \u03b1 protects pancreatic \u03b2-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress","volume":"293","author":"Zhou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1753-0407.12139","article-title":"Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL\/6 mice CSK9PC57BL\/6","volume":"7","author":"Mbikay","year":"2015","journal-title":"J. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155291","article-title":"Pancreatic PCSK9 controls the organization of the \u03b2-cell secretory pathway via LDLR-cholesterol axis","volume":"136","author":"Marku","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.heliyon.2023.e19371_bib55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e19371_bib56","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00125-015-3659-8","article-title":"The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis","volume":"58","author":"Bonnefond","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.heliyon.2023.e19371_bib57","article-title":"Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice","volume":"1866","author":"Peyot","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.heliyon.2023.e19371_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2021.03.044","article-title":"Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function","volume":"326","author":"Ramin-Mangata","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2023.e19371_bib59","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","article-title":"Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9","volume":"55","author":"Humphries","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/MPA.0000000000000486","article-title":"Cholesterol in pancreatic \u03b2-cell death and dysfunction: underlying mechanisms and pathological implications","volume":"45","author":"Paul","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.heliyon.2023.e19371_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2337\/db11-1341","article-title":"Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired \u03b2-cell function","volume":"61","author":"Kruit","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib62","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/ATVBAHA.114.304477","article-title":"Atheroma progression in hyporesponders to statin therapy","volume":"35","author":"Kataoka","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019525","article-title":"Circulating mature PCSK9 level predicts diminished response to statin therapy","volume":"10","author":"Kuyama","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2023.e19371_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/srep14076","article-title":"Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis","volume":"5","author":"Gotoh","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1139\/Y08-098","article-title":"Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention","volume":"87","author":"McNamara","year":"2009","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134725","article-title":"Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib69","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib70","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib71","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib72","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014129","article-title":"Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): a pooled analysis of phase 2 and phase 3 studies","volume":"9","author":"Toth","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2023.e19371_bib73","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2023.e19371_bib74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (Low-Density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib75","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 Years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.heliyon.2023.e19371_bib76","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib77","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e19371_bib78","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib79","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.heliyon.2023.e19371_bib80","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/dom.13235","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis","volume":"20","author":"Cao","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib81","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40256-019-00386-w","article-title":"Safety of proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies in regard to diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Chen","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.heliyon.2023.e19371_bib82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/dc17-2563","article-title":"Comment on de Carvalho et al. Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: a Systematic Review and Meta-analysis With Over 96,000 Patient-Years","volume":"41","author":"Cao","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib84","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib85","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","article-title":"PCSK9 inhibition and risk of diabetes: should we worry?","volume":"24","author":"Carugo","year":"2022","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib86","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.heliyon.2023.e19371_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4940825","article-title":"Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies","author":"Rodr\u00edguez","year":"2019","journal-title":"Oxid Med Cell Longev 2019"},{"key":"10.1016\/j.heliyon.2023.e19371_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/nu12010082","article-title":"Pterostilbene prevents early diabetic retinopathy alterations in a rabbit experimental model","volume":"12","author":"Mill\u00e1n","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.heliyon.2023.e19371_bib89","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.lfs.2006.12.036","article-title":"Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy","volume":"80","author":"Kumar","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib90","doi-asserted-by":"crossref","first-page":"H833","DOI":"10.1152\/ajpheart.00418.2009","article-title":"Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy","volume":"298","author":"Sulaiman","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712608","article-title":"Effects of citrus fruit juices and their bioactive components on inflammation and immunity: a narrative review","volume":"12","author":"Miles","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib92","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-010-1525-4","article-title":"Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats","volume":"68","author":"Kapetanovic","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib93","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/10715762.2019.1635252","article-title":"Pterostilbene reverses palmitic acid mediated insulin resistance in HepG2 cells by reducing oxidative stress and triglyceride accumulation","volume":"53","author":"Malik","year":"2019","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib94","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbrc.2018.03.035","article-title":"AMPK activation by pterostilbene contributes to suppression of hepatic gluconeogenic gene expression and glucose production in H4IIE cells","volume":"498","author":"Ren","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e19371_bib95","first-page":"365","article-title":"Pterostilbene ameliorates glycemic control, dyslipidemia and liver injury in type 2 diabetes rats","volume":"33","author":"Zhang","year":"2020","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2017.06.015","article-title":"Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats","volume":"182","author":"Kosuru","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172526","article-title":"Antidiabetic effects of pterostilbene through PI3K\/Akt signal pathway in high fat diet and STZ-induced diabetic rats","volume":"859","author":"Sun","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib98","article-title":"Pterostilbene increases LDL metabolism in HL-1 cardiomyocytes by modulating the PCSK9\/HNF1\u03b1\/SREBP2\/LDLR signaling cascade","volume":"10","author":"Lin","year":"2021","journal-title":"Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression, Antioxidants (Basel)"},{"key":"10.1016\/j.heliyon.2023.e19371_bib99","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12951-021-00928-y","article-title":"Nanoparticles prepared from pterostilbene reduce blood glucose and improve diabetes complications","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cbi.2008.11.008","article-title":"Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats","volume":"179","author":"Palsamy","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.heliyon.2023.e19371_bib101","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2014.09.047","article-title":"Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway","volume":"745","author":"Hao","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib102","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1248\/bpb.b17-01027","article-title":"Polydatin improves glucose and lipid metabolisms in insulin-resistant HepG2 cells through the AMPK pathway","volume":"41","author":"Hao","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.heliyon.2023.e19371_bib103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mce.2012.06.008","article-title":"Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-\u03baB signaling pathway in rat glomerular mesangial cells","volume":"362","author":"Xie","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-015-0325-x","article-title":"Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"15","author":"Wang","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/jf010153l","article-title":"Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom","volume":"50","author":"Khokhar","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165856","article-title":"Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511\/miR-29b\/KDM2A axis","volume":"1866","author":"Zhao","year":"2020","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.heliyon.2023.e19371_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25143146","article-title":"Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer","volume":"25","author":"Almatroodi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.heliyon.2023.e19371_bib108","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clnu.2015.05.003","article-title":"Therapeutic effect of high-dose green tea extract on weight reduction: a randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Chen","year":"2016","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.heliyon.2023.e19371_bib109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1142\/S0192415X20500172","article-title":"(-)-Epigallocatechin gallate promotes MicroRNA 145 expression against myocardial hypoxic injury through dab2\/wnt3a\/\u03b2-catenin","volume":"48","author":"Lin","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib110","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.7150\/ijms.46696","article-title":"Epigallocatechin-3-gallate preconditioned Adipose-derived Stem Cells confer Neuroprotection in aging rat brain","volume":"17","author":"Hsieh","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.freeradbiomed.2020.07.037","article-title":"Role of Nrf2 dysfunction in the pathogenesis of diabetic nephropathy: therapeutic prospect of epigallocatechin-3-gallate","volume":"160","author":"Mohan","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22508","article-title":"Beneficial effects of (-)-epigallocatechin-3-O-gallate on diabetic peripheral neuropathy in the rat model","volume":"34","author":"Abo-Salem","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108065","article-title":"A prodrug of epigallocatechin-3-gallate alleviates high glucose-induced pro-angiogenic factor production by inhibiting the ROS\/TXNIP\/NLRP3 inflammasome axis in retinal M\u00fcller cells","volume":"196","author":"Du","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107412","article-title":"Epigallocatechin-3-gallate prevents inflammation and diabetes -Induced glucose tolerance through inhibition of NLRP3 inflammasome activation","volume":"93","author":"Zhang","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2023.e19371_bib115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-020-02362-4","article-title":"Beneficial impact of epigallocatechingallate on LDL-C through PCSK9\/LDLR pathway by blocking HNF1\u03b1 and activating FoxO3a","volume":"18","author":"Cui","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib116","doi-asserted-by":"crossref","first-page":"29252","DOI":"10.1074\/jbc.M113.481473","article-title":"FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin\/kexin type 9 (Pcsk9) gene expression","volume":"288","author":"Tao","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib117","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/pcp\/pcr062","article-title":"Isoquinoline alkaloid biosynthesis is regulated by a unique bHLH-type transcription factor in Coptis japonica","volume":"52","author":"Yamada","year":"2011","journal-title":"Plant Cell Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113839","article-title":"Plant isoquinoline alkaloids: advances in the chemistry and biology of berberine","volume":"226","author":"Singh","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-319-41334-1_2","article-title":"Berberine and its role in chronic disease","volume":"928","author":"Cicero","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib120","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14712598.2012.704014","article-title":"Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials","volume":"12","author":"Derosa","year":"2012","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.heliyon.2023.e19371_bib121","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cbdv.200900041","article-title":"Habitat-dependent variations in berberine content of Berberis asiatica roxb. Ex. DC. In kumaon, western himalaya","volume":"7","author":"Andola","year":"2010","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.heliyon.2023.e19371_bib122","doi-asserted-by":"crossref","first-page":"E148","DOI":"10.1152\/ajpendo.00211.2007","article-title":"Berberine improves glucose metabolism through induction of glycolysis","volume":"294","author":"Yin","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2023.e19371_bib123","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.metabol.2013.02.007","article-title":"Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase","volume":"62","author":"Chang","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.heliyon.2023.e19371_bib124","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.mce.2009.12.027","article-title":"Berberine modulates insulin signaling transduction in insulin-resistant cells","volume":"317","author":"Liu","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib125","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.2337\/db06-0006","article-title":"Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states","volume":"55","author":"Lee","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib126","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ejphar.2008.12.056","article-title":"Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate\/high-fat diet-induced diabetic rats","volume":"606","author":"Zhou","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib127","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1472-6882-14-188","article-title":"Berberine moderates glucose metabolism through the GnRH-GLP-1 and MAPK pathways in the intestine","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib128","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.21037\/atm-20-8106","article-title":"Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE(-\/-) mice by down-regulating PCSK9 via ERK1\/2 pathway","volume":"9","author":"Ma","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib129","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2023.e19371_bib130","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","article-title":"Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1\u03b1 protein expression through the ubiquitin-proteasome degradation pathway","volume":"290","author":"Dong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1479-5876-12-103","article-title":"Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats","volume":"12","author":"Jia","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib132","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11655-014-1775-1","article-title":"Inhibition of proprotein convertase subtilisin\/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia","volume":"21","author":"Liu","year":"2015","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib133","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1034\/j.1600-0773.2002.t01-1-910403.x","article-title":"The involvement of P-glycoprotein in berberine absorption","volume":"91","author":"Pan","year":"2002","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib134","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/jps.10268","article-title":"P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers","volume":"91","author":"Maeng","year":"2002","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871529X18666180201130340","article-title":"Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells","volume":"18","author":"Ochin","year":"2018","journal-title":"Cardiovasc. Hematol. Disord.: Drug Targets"},{"key":"10.1016\/j.heliyon.2023.e19371_bib136","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/jcb.27102","article-title":"Berberrubine and its analog, hydroxypropyl-berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol-lowering effects in human hepatoma HepG2 cells","volume":"120","author":"Cao","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib137","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.apsb.2019.06.006","article-title":"Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin\/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia","volume":"9","author":"Wu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2023.e19371_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104994","article-title":"Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents","volume":"113","author":"Fan","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/md14040064","article-title":"Anthraquinones and derivatives from marine-derived fungi: structural diversity and selected biological activities","volume":"14","author":"Fouillaud","year":"2016","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.heliyon.2023.e19371_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104315","article-title":"Aloe-emodin attenuates myocardial infarction and apoptosis via up-regulating miR-133 expression","volume":"146","author":"Yu","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phymed.2018.06.029","article-title":"Rhein protects the myocardiac cells against hypoxia\/reoxygention-induced injury by suppressing GSK3\u03b2 activity","volume":"51","author":"Liu","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.heliyon.2023.e19371_bib142","article-title":"Rhein antagonizes P2X7 receptor in rat peritoneal macrophages","volume":"5","author":"Hu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/MSM.905496","article-title":"Emodin attenuates bleomycin-induced pulmonary fibrosis via anti-inflammatory and anti-oxidative activities in rats","volume":"24","author":"Tian","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.heliyon.2023.e19371_bib144","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11418-013-0810-z","article-title":"Antidyslipidemic effect and antioxidant activity of anthraquinone derivatives from Rheum emodi rhizomes in dyslipidemic rats","volume":"68","author":"Mishra","year":"2014","journal-title":"J. Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1440-1681.2008.05051.x","article-title":"Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats","volume":"36","author":"Zhao","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib146","first-page":"3262","article-title":"Emodin alleviates CCl4-induced liver fibrosis by suppressing epithelial-mesenchymal transition and transforming growth factor-\u03b21 in rats","volume":"18","author":"Liu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib147","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11255-017-1757-x","article-title":"Emodin ameliorates renal fibrosis in rats via TGF-\u03b21\/Smad signaling pathway and function study of Smurf 2","volume":"50","author":"Ma","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib148","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.apsb.2019.04.003","article-title":"Emodin alleviates cardiac fibrosis by suppressing activation of cardiac fibroblasts via upregulating metastasis associated protein 3","volume":"9","author":"Xiao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2023.e19371_bib149","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2015.11.045","article-title":"Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway","volume":"770","author":"Li","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.fitote.2009.08.020","article-title":"Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice","volume":"81","author":"Xue","year":"2010","journal-title":"Fitoterapia"},{"key":"10.1016\/j.heliyon.2023.e19371_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202100675","article-title":"Effect of emodin on hyperlipidemia and hepatic lipid metabolism in zebrafish larvae fed a high-cholesterol diet","volume":"19","author":"He","year":"2022","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.heliyon.2023.e19371_bib152","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41401-020-0392-8","article-title":"Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin\/kexin type 9 in hyperlipidemic rats","volume":"41","author":"Su","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2023.e19371_bib153","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","article-title":"Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden","volume":"7","author":"Svanstr\u00f6m","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111778","article-title":"The HIF-2\u03b1\/PPAR\u03b1 pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis","volume":"140","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e19371_bib157","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib158","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-018-0689-9","article-title":"Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db\/db mice through a HNF-1a dependent mechanism","volume":"17","author":"Yang","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib159","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/kexin type 9 expression","volume":"44","author":"Verg\u00e8s","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101284","article-title":"Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins","volume":"48","author":"Verg\u00e8s","year":"2022","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.heliyon.2023.e19371_bib161","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2337\/cd21-pe01","volume":"39","year":"2021","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib162","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib163","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2337\/dc15-0658","article-title":"Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes","volume":"38","author":"Xu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.heliyon.2023.e19371_bib164","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2337\/db13-0194","article-title":"Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice","volume":"63","author":"Geerling","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11892-017-0829-8","article-title":"Metformin: new preparations and nonglycemic benefits","volume":"17","author":"Fujita","year":"2017","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147680","article-title":"Metformin affects cardiac arachidonic acid metabolism and cardiac lipid metabolite storage in a prediabetic rat model","volume":"22","author":"Miklankova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib167","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1161\/ATVBAHA.120.315708","article-title":"New insight into metformin-induced cholesterol-lowering effect crosstalk between glucose and cholesterol homeostasis via ChREBP (Carbohydrate-Responsive element-binding protein)-mediated PCSK9 (proprotein convertase subtilisin\/kexin type 9) regulation","volume":"41","author":"Hu","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib168","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12020-022-03022-x","article-title":"Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin\/kexin type 9 (PCSK9) in liver cells","volume":"76","author":"Ali","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.heliyon.2023.e19371_bib169","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41401-021-00686-5","article-title":"Kanglexin delays heart aging by promoting mitophagy","volume":"43","author":"Li","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2023.e19371_bib170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41401-019-0307-8","article-title":"Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis","volume":"41","author":"Bian","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2023.e19371_bib171","article-title":"Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-\u03b21\/ERK1\/2 noncanonical pathway","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110933","article-title":"Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1\/ERK signaling","volume":"132","author":"Zhao","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e19371_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110802","article-title":"Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK\/SREBP-2\/PCSK9\/LDLR signalling pathway","volume":"133","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2023.e19371_bib174","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2023.e19371_bib175","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib176","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib177","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1499-2671(09)33072-5","article-title":"Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis","volume":"33","author":"Plutzky","year":"2009","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093240","article-title":"The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective","volume":"21","author":"Agius","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib179","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ptr.7306","article-title":"Old dog, new tricks: polydatin as a multitarget agent for current diseases","volume":"36","author":"Ye","year":"2022","journal-title":"Phytother Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105315","article-title":"Effect of eugenol treatment in hyperglycemic murine models: a meta-analysis","volume":"165","author":"Carvalho","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib181","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.fitote.2013.12.023","article-title":"Effects of eugenol on hepatic glucose production and AMPK signaling pathway in hepatocytes and C57BL\/6J mice","volume":"93","author":"Jeong","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1016\/j.heliyon.2023.e19371_bib182","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lfs.2018.11.034","article-title":"Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet\/streptozotocin-induced diabetic rat","volume":"216","author":"Al-Trad","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib183","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11010-013-1824-2","article-title":"Ameliorating effect of eugenol on hyperglycemia by attenuating the key enzymes of glucose metabolism in streptozotocin-induced diabetic rats","volume":"385","author":"Srinivasan","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2019.109513","article-title":"Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis","volume":"136","author":"Zia","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.heliyon.2023.e19371_bib185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000499480","article-title":"Naringin ameliorates streptozotocin-induced diabetes through forkhead box M1-mediated beta cell proliferation","volume":"206","author":"Subramanian","year":"2018","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.heliyon.2023.e19371_bib186","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000496506","article-title":"Naringin (4',5,7-trihydroxyflavanone 7-rhamnoglucoside) attenuates \u03b2-cell dysfunction in diabetic rats through upregulation of PDX-1","volume":"206","author":"Subramanian","year":"2018","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.heliyon.2023.e19371_bib187","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1021\/acs.jafc.8b02696","article-title":"Naringin activates AMPK resulting in altered expression of SREBPs, PCSK9, and LDLR to reduce body weight in obese C57bl\/6J mice","volume":"66","author":"Sui","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib188","doi-asserted-by":"crossref","first-page":"17212","DOI":"10.1002\/jcp.28528","article-title":"Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications","volume":"234","author":"Joshi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib189","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/0929867323666160909153707","article-title":"The antidiabetic potential of quercetin: underlying mechanisms","volume":"24","author":"Eid","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib190","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02248-5","article-title":"Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus","volume":"11","author":"Zu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib191","first-page":"893","article-title":"Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPAR\u03b3, LXR\u03b1 and ABCA1","volume":"44","author":"Jia","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib192","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1039\/C7FO00562H","article-title":"Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells","volume":"8","author":"Choi","year":"2017","journal-title":"Food Funct."},{"key":"10.1016\/j.heliyon.2023.e19371_bib193","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11655-019-2942-9","article-title":"Effect of quercetin on atherosclerosis based on expressions of ABCA1, LXR-\u03b1 and PCSK9 in ApoE(-\/-) mice","volume":"26","author":"Li","year":"2020","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib194","first-page":"799","article-title":"Quercetin protects against ox-LDL-induced injury via regulation of ABCAl, LXR-\u03b1 and PCSK9 in RAW264.7 macrophages","volume":"18","author":"Li","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2023.e19371_bib195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00394-013-0546-2","article-title":"Fructooligosaccharide augments benefits of quercetin-3-O-\u03b2-glucoside on insulin sensitivity and plasma total cholesterol with promotion of flavonoid absorption in sucrose-fed rats","volume":"53","author":"Phuwamongkolwiwat","year":"2014","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.heliyon.2023.e19371_bib196","doi-asserted-by":"crossref","first-page":"197.e191","DOI":"10.1016\/j.ajog.2018.04.045","article-title":"Modulation of nuclear factor-\u03baB signaling and reduction of neural tube defects by quercetin-3-glucoside in embryos of diabetic mice","volume":"219","author":"Tan","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib197","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/biof.5520310307","article-title":"Antidiabetic and antioxidative effects of Annona squamosa leaves are possibly mediated through quercetin-3-O-glucoside","volume":"31","author":"Panda","year":"2007","journal-title":"Biofactors"},{"key":"10.1016\/j.heliyon.2023.e19371_bib198","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","article-title":"Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin\/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture","volume":"4","author":"Mbikay","year":"2014","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.heliyon.2023.e19371_bib199","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700729","article-title":"Mice fed a high-cholesterol diet supplemented with quercetin-3-glucoside show attenuated hyperlipidemia and hyperinsulinemia associated with differential regulation of PCSK9 and LDLR in their liver and pancreas","volume":"62","author":"Mbikay","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10787-015-0237-0","article-title":"Novel quercetin-3-O-glucoside eicosapentaenoic acid ester ameliorates inflammation and hyperlipidemia","volume":"23","author":"Sekhon-Loodu","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.heliyon.2023.e19371_bib201","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaim.2018.01.003","article-title":"In vitro and in vivo evaluation of pterostilbene for the management of diabetic complications","volume":"11","author":"Dodda","year":"2020","journal-title":"J. Ayurveda Integr. Med."},{"key":"10.1016\/j.heliyon.2023.e19371_bib202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2016.02.054","article-title":"Anti-hyperlipidemic and anti-peroxidative role of pterostilbene via Nrf2 signaling in experimental diabetes","volume":"777","author":"Bhakkiyalakshmi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib203","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/jcp.26835","article-title":"Differential proteomic profiling identifies novel molecular targets of pterostilbene against experimental diabetes","volume":"234","author":"Dornadula","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jnutbio.2017.02.015","article-title":"Role of pterostilbene in attenuating immune mediated devastation of pancreatic beta cells via Nrf2 signaling cascade","volume":"44","author":"Sireesh","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib205","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/1753-0407.12296","article-title":"Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities","volume":"8","author":"Liu","year":"2016","journal-title":"J. Diabetes"},{"key":"10.1016\/j.heliyon.2023.e19371_bib206","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2015.10.126","article-title":"Effect of resveratrol on sirtuins expression and cardiac complications in diabetes","volume":"468","author":"Bagul","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e19371_bib207","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.gene.2015.06.019","article-title":"Resveratrol improves hepatic insulin signaling and reduces the inflammatory response in streptozotocin-induced diabetes","volume":"570","author":"Sadi","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.heliyon.2023.e19371_bib208","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1748-717X-6-144","article-title":"Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways","volume":"6","author":"Rashid","year":"2011","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib209","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/FJC.0000000000000504","article-title":"Resveratrol ameliorates cardiac dysfunction by inhibiting apoptosis via the PI3K\/Akt\/FoxO3a pathway in a rat model of diabetic cardiomyopathy","volume":"70","author":"Wu","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000369718","article-title":"Modulation of SIRT1-Foxo1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance","volume":"35","author":"Sin","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib211","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2019.05.019","article-title":"Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor \u03b1-mediated pathway in L02 cells","volume":"855","author":"Jing","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib212","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/mnfr.201400366","article-title":"Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells","volume":"58","author":"Tai","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.heliyon.2023.e19371_bib213","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2174\/1568026615666150619142519","article-title":"Curcumin: a natural product for diabetes and its complications","volume":"15","author":"Nabavi","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.heliyon.2023.e19371_bib214","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13880209.2019.1594311","article-title":"Curcumin ameliorates gestational diabetes in mice partly through activating AMPK","volume":"57","author":"Lu","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.heliyon.2023.e19371_bib215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejps.2012.04.018","article-title":"Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway","volume":"47","author":"Soetikno","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2023.e19371_bib216","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.numecd.2019.06.001","article-title":"Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake","volume":"29","author":"Lupo","year":"2019","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.heliyon.2023.e19371_bib217","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/jmf.2019.0168","article-title":"Efficacy of nutraceutical combination of monacolin K, berberine, and silymarin on lipid profile and PCSK9 plasma level in a cohort of hypercholesterolemic patients","volume":"23","author":"Formisano","year":"2020","journal-title":"J. Med. Food"},{"key":"10.1016\/j.heliyon.2023.e19371_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110984","article-title":"Therapeutic effect of berberine on metabolic diseases: both pharmacological data and clinical evidence","volume":"133","author":"Xu","year":"2021","journal-title":"Biomed. Pharmacother."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023065799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023065799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:59:39Z","timestamp":1784926779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023065799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":218,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2405844023065799"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19371","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e19371"}}